4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000112
Chief Executive Officer sold 25,000 shares at an average $95.60 ($2,390,125)
- Chief Executive Officer acquired 25,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Option exercise 10b5-1 | +25,000 | $7.80 | $195,000 | 948,128 | D: show line 1 in the form |
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Sale 10b5-1 | −6,466 | $94.77 | $612,794 | 941,662 | D: show line 2 in the form |
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Sale 10b5-1 | −15,036 | $95.64 | $1,437,987 | 926,626 | D: show line 3 in the form |
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Sale 10b5-1 | −2,442 | $96.70 | $236,147 | 924,184 | D: show line 4 in the form |
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Sale 10b5-1 | −756 | $97.45 | $73,676 | 923,428 | D: show line 5 in the form |
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Sale 10b5-1 | −300 | $98.40 | $29,521 | 923,128 | D: show line 6 in the form |
| Open-market sales · 25,000 sh · avg $95.60 · $2,390,125 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Klein Lawrence Otto Chief Executive Officer | 2026-11-02 | Option exercise · Employee Warrant (right to buy) 10b5-1 | −25,000 | 1,503,513 | D: show line 7 in the form |
Loading xslF345X06/form4.xml…